weixin.sogou.com·· 8 hours agoPickScore92
NMPA Grants World-First Approval to Bayer's Asundexian to Reduce Ischemic Stroke or High-Risk TIA Risk
In brief
The NMPA has granted the world's first approval of Bayer's asundexian to reduce stroke risk in adults with ischemic stroke or high-risk transient ischemic attack (TIA), excluding cardioembolic stroke. The drug received priority review, with approval taking about half a year from acceptance.
Why it matters
Both global and Chinese subgroup data report ischemic stroke risk reduction and major bleeding risk, enabling direct comparison of local and global results.
Source: weixin.sogou.com · weixin.sogou.com